May 17, 2020

This Terrifying Video Captures a Dramatic Rescue of a Skydiver Having a Seizure

Video
Skydiver
Seizure
epilepsy
Admin
2 min
Jones said he woke up at 3,000 feet, under the parachute, and landed safely.
“Possibly the scariest moment of my life,” reads the caption under the viral video posted on YouTube of a man suffering from a seizure while...

“Possibly the scariest moment of my life,” reads the caption under the viral video posted on YouTube of a man suffering from a seizure while free falling.

Christopher Jones, a 22-year-old Australian, suffered a seizure during a skydiving training course on November 14, 2014 at around 9,000 ft. His instructor, who had to make two attempts to deploy Jones’ parachute, caught the rescue on video.

Jones' lifelong dream of becoming a pilot was dashed when he was diagnosed with epilepsy. After going four years without a seizure, he decided to try skydiving to experience the same feeling pilots do, according to Australia's ABC News.

"I've always wanted to have the feeling of flight, so I just thought considering I can't fly a plane due to my condition, I thought I'd give it a go," Jones said.

During the skydive in the video below, the fun jump quickly turned scary when instructor Sheldon McFarlane noticed Jones roll onto his back. The video shows McFarlane trying to approach Jones to grab his ripcord, but he fails, and Jones plummets further toward the earth. On McFarlane's second try, he successfully deploys the chute.

McFarlane says Jones would have landed safely even if he hadn't reached the ripcord. Jones was equipped with an automatic activation device that would have deployed the parachute once he reached a lower altitude.

"At no time was I worried he was going to hit the ground without a parachute, but given the circumstances and where we were I thought it would be better to get him under parachute earlier than later," McFarlane told ABC News. "As far as difficult, yeah, it was OK. I got him."

Follow us on Twitter (@HealthcareGlbl) and like us on Facebook! 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article